Ovoca Bio Dividends OVB

Dividends

No Dividend Data for OVB

Top Dividend Posts

Top Posts
Posted at 01/3/2024 14:32 by mdi hTtps://www.proactiveinvestors.co.uk/companies/news/946551/how-futura-medical-turned-med3000-into-a-near-billion-pound-opportunity-946551.htmlWhy haven't OVB turned the placebo nasal spray from their failed study into a similar 'near billion pound opportunity'? Read Full Thread Reply
Posted at 02/2/2024 11:10 by jimtech As I had difficulty asking questions at the OVB AGM I sent some later by email. Here are their responses which might be of interest. Bear in mind I received their email below on 4th December so it is a couple of months old: [JT 2] Clearly the recent Australian / New Zealand Orenetide trial results were extremely disappointing. It would seem to me that there has either been a flaw in previous trials or in this recent one. Which one is it? [OVB] We strongly disagree that the disappointing results of a recent study mean that there is a flaw in this or the previous studies. Clinical studies are very complex scientific process with risks and uncertain outcome, despite any previous results. This was disclosed in Ovoca’s Re-Admission Document for the Proposed Acquisition of IVIX (Part 2 “Risk factors”, “RISKS RELATING TO THE ENLARGED GROUP AND THE SECTOR IN WHICH IT OPERATES” at p. 19-20): “…Clinical testing is expensive and can take many years to complete and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process… The results of … earlier clinical trials may not be predictive of the results of later stage clinical trials. For example, the results generated to date in … Phase I or Phase II clinical trials for the Enlarged Group’s product candidate does not ensure that later clinical trials will demonstrate similar results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical trials…” Unfortunately, it seems that this scientific risk has been realized. [JT 3] Who oversaw the previous Russian Orenetide (BP-101) trials? Was it the management of IVIX? [OVB] The previous Russian Orenetide (BP-101) trials were administrated by one of the leading Russian Contract Research Organizations (CRO) – OCT Clinical Trials. Trials Sponsor oversight (which is mandatory according to ICH GCP standard on clinical trials) was done by the management of IVIX. This is public information, but disclosed in the Russian clinical trials registry (however we have checked – automated page translation into English is available in the Chrome browser, and we assume it should be available in other major browsers). Also, public information is available in the Clinicaltrials.gov registry: hxxps://www.clinicaltrials.gov/study/NCT03463707. [JT 4] Is there any future at all for Orenentide? [OVB] For the moment we are not ready to make any conclusions – study report is still in process, and additional internal assessments are ongoing. The Company will determine the appropriate future strategy regarding the development of Orenetide, including whether the Company can and should continue with its development of this product. [JT 5] What is the future strategy for Ovoca Bio now? [OVB] Again, we are assessing the Orenetide trial results and any implications this may have for the wider strategy of the Company, including a number of potential strategies. We will keep shareholders informed on any developments as and when appropriate. Please keep in mind that while answering to this question we are limited by AIM rules on disclosure of material and insider information, so our reply may not contain any significant comments / material updates beyond anything that already has been published via RNS. Read Full Thread Reply
Posted at 31/8/2023 19:09 by dave4545 So market cap has closed exactly the same as cash in RNS end of July. Given there is always a option to turn into a shell and move in a new direction I feel I might as well hold especially as current stake is only worth less than £2k. Remember when ITS collapsed then turned into a shell and 25 bagged from their low. Lets see what Ovb decide to do Read Full Thread Reply
Posted at 10/5/2023 10:34 by dave4545 Good job OVB sold most of their poly shares shame they did not have the sense to sell the lot when they were £20 a share. And still we wait for trial results. I'm trying to be logical here but if they were no good/bad then they would have told us by now but then again I suppose that could apply if they were positive Read Full Thread Reply
Posted at 13/12/2022 11:12 by dave4545 OVB are not the raising type. It's all on the trial results, if they are positive and price soars they would have no trouble securing money in the market or from a pharma. 4.6p bid now, how low does this go. Read Full Thread Reply
Posted at 19/10/2022 11:34 by dave4545 Not much stock around again. Clearly until it reaches a level people will sell again there is not much stock. 2 small buys had to pay decent premiums. Still nobody seems to be around the forums on ovb except me Read Full Thread Reply
Posted at 30/6/2022 07:58 by dave4545 There's the results then Mickinvest Standard set of results. Cash down to £5-6 mil, losses up due to the phase 11 trial. But a £8 mil stock with £5-6 mil cash well into a phase 11 trial with approval for another drug that they are building a "manufacturing process" seems bonkers But in this market I doubt miracles will happen today, Ovb is just not as popular as stocks like Avct, if they issued exactly the same news with same market cap they would be going nuts about it. Held 3 years now and I will hold for trial results which I still think will be positive Read Full Thread Reply
Posted at 18/5/2022 09:38 by dave4545 Looks like Ovb got a nudge from somewhere or people waiting for blue then piling in. Read Full Thread Reply
Posted at 06/2/2022 11:21 by hedgehog 100 Thanks to Afzal Valli for this Twitter post on Friday: Afzal Valli @AfzalValli· 4 Feb #OVB "I’ve a feeling there’s something coming shortly This could be a huge piece of news. Potential to build towards £1 MA and commercial deals to follow -- The Marketing Authorization ("MA") application for orenetide is still under review by the Russian Ministry of Health" And apparently this poster has hoovered up most of the available OVB stock in two large buys on Friday: Recent Share Trades for Ovoca Bio (OVB) Date Time Trade Prc Volume Buy/Sell Bid Ask Value 04-Feb-22 15:50:41 11.40 87,636 Unknown* 11.00 12.00 9,991 O 04-Feb-22 16:31:02 12.00 10,000 Buy* 11.00 12.00 1,200 O 04-Feb-22 16:14:49 11.985 834 Buy* 10.50 12.00 99.95 O 04-Feb-22 16:14:34 11.985 834 Buy* 10.50 12.00 99.95 O 04-Feb-22 16:14:04 11.985 834 Buy* 10.50 12.00 99.95 O 04-Feb-22 16:11:20 12.00 1,666 Buy* 10.50 12.00 199.92 O 04-Feb-22 16:04:22 11.985 8,000 Buy* 10.50 12.00 958.80 O 04-Feb-22 15:49:03 11.50 173,830 Buy* 10.00 11.50 19.99k O 04-Feb-22 08:45:22 10.00 5,000 Sell* 10.00 11.50 500.00 O 04-Feb-22 08:36:21 11.50 9 Buy* 10.00 11.50 1.04 O Read Full Thread Reply
Posted at 24/1/2022 10:04 by hedgehog 100 OVB's initial marketing authorisation application with the Russian Ministry of Health, for BP-101, took 12 months & 20 days for a decision: 12/09/2019 06:01 UK Regulatory (RNS & others) Ovoca Bio PLC Filing of Marketing Authorisation Application LSE:OVB Ovoca Bio Plc 02/10/2020 06:00 UK Regulatory (RNS & others) Ovoca Bio PLC Update re Russian Marketing Authorisation LSE:OVB Ovoca Bio Plc The reapplication was submitted 12 months and 19 days ago, so on the basis of the previous timescale news should be imminent: 05/01/2021 07:00 UK Regulatory (RNS & others) Ovoca Bio PLC Re-Filing of Marketing Authorisation Application LSE:OVB Ovoca Bio Plc Read Full Thread Reply